There is one study that shows the efficacy of apigenin in the murine DSS colitis model through blocking the inflammasome vias by the production of IL-1β and downregulation of iNOS and COX-2 and decreasing serum levels of matrix metalloproteinase-3 63. This evidence concerns the gene IL1B and colitis.